Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 12 In PIONEER 10, oral sema 14 mg showed statistically significant reduction in HbA1c and weight vs sc dulaglutide Reduction in HbA1c Reduction in body weight (kg) Number of adverse events HbA1c reduction (%)¹ Oral semaglutide Weight Oral semaglutide Sc dula Sc dulaglutide² loss (kg) 1 3 7 14 0.75 3 7 14 mg³ mg mg mg mg mg mg 0.75 mg Dose (mg) 3 7 14 0.75 0.0 2.01 1.1kg GI adverse events 31% 39% 54% 40% -0.4 -0.8 -0.7%+ 1.0 0.1 kg 0.0 Consti. 9% 12% 15% 9% -1.2 Nausea 5% 8% 9% 9% -1.3% -1.0 -1.6 -1.4% -1.0 kg* -2.0 -1.8%* Disc. rate due to AE 3% 6% 6% 3% -2.0 -1.9 kg* 1 Results illustrated by using the secondary statistical method called hypothetical estimand after 52 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide 2 Subcutaneous dulaglutide 0.75 mg is the approved dose in Japan +Statistically significantly lower versus 0.75 mg dulaglutide *Statistically significant versus 0.75 mg dulaglutide GI: Gastrointestinal; Consti: Constipation; Disc. rate: Discontinuation rate; AE: Adverse events; Sema: Semaglutide; Dula: Dulaglutide; Sc: Subcutaneous novo nordisk

View entire presentation